Sudden death arises from distrubances in the regular excitation of
the heart.
Mostly, disturbances in the regular rhythm arise from
either premature excitation or by breaking an excitation wave as it
collides with either an obstacle, a region of reduced excitability
or another wave. A heart is always vulnerable to disturbances
in the regular excitation process. Vulnerability occurs because there
is an asymmetry of excitable tissue, caused either by the passage of
a previous wave or by the anisotropic nature of coupling between cells.
Vulnerability can be amplifed by reducing the excitability of the
heart, i. e. shifting the excitability closer to the boundary between
excitation and failure to excite. When the heart beats regularly,
the electrocardiogram reveals a regular pattern of changes in potential
as shown here.
However, if the heart is vulnerable, then the regular pattern of
excitation of the heart can be interrupted by a premature excitation.
All to often the wavefront associated with the premature excitation is
not completely formed (i.e. continuous), but broken and the ends of the
broken front begin to curl, signaling the formation of a spiral wave.
Depending on the excitability of the heart, the spiral wave will rotate
around a stationary core or will meander. If the spiral wave breaks and
forms additional spirals, then the heart will no longer be stimulated in
a regular manner, but in an irregular manner - with different regions of the
heart excited asynchronously. The result is an electrocardiogram that
reveals non-repetitive activation as shown here.
Voltage sensitive optical dyes reveal the spiral nature of wave motion
in the heart as shown here (from Art Winfree's site).
A propagating wave of excitation in the heart can be broken (a precursor
of spiral wave formation) by manipulating the excitability of the heart.
The excitability can be altered by drugs, by decouping cells, by
ischemic regions and by premature excitation. A wave propagating in
a region that contain regions of excitable and regions of unexcitable
tissue will be broken. Because there are more unexcited cells adjacent to the
ends of a front than adjacent to cells within the front, the ends travel
slower (due to the fact that an excited cell has a limited amount of
charge available to excite neighboring cells). This results in curling
of the ends and the formation of a spiral wave.
I have explore several conditions associated with altering excitability,
including genetic alteration of the Na channel and class I antiarrhythmic
drugs. Earlier, we explore breaking waves with obstacles. Here
are links to these papers.
Studies of the relationship between excitability, spiral wave stability
and spiral wave fragmentation were described here
My curiosity about the relationship between vulnerability and altered
excitability was triggered by our observation that often substance
abusers appear in emergency rooms with cardiac tachyarrhythmias. We found
that most abused substances, cocaine, tricyclic antidepressants, darvon
(propoxyphene) all are use-dependent Na channel blockers. Here was
our initial observation
Recent observations about the role of the
spatial gradient of excitability on the VP
- with these, we outline the link between drug unbinding which
controls the gradient of excitability trailing an activation wavefront. These
are the missing links from our story that started 10 years ago.
1991-1998: Original Ideas - slightly stale, but still useful history
The CAST and the SWORD
Several large clinical trials (CAST and SWORD) failed to show that frequenly used
antiarrhythmic drugs could actually reduce the rate of sudden
cardiac death. To the contrary - they demonstrated a 2x to 3x increase
in the rate of sudden cardiac death. For the past 20 years, Gus
Grant and I have been studying - at the single channel and whole cell
level, the interaction of antiarrhythmic drugs with membrane ion
channels. We developed a simple model of drug interaction with
ion channels,
the guarded receptor model, and verified it
with numerous experiments (see bibliography).
With Maddy Spach, we have explored the role of propagation
in wavefront formation and with Josef Starobin, we have developed
an accurate model of front formation. Together, these results revealed
a previously unknown feature of use-dependent ion channel blockade -
prolongation of the
cardiac vulnerable period . Recent studies by us
in rabbit atrial tissue confirmed these hypotheses.
The guard and another guard - protecting the channel
In mid 1996, Art Winfree invited me to write a tutorial for the January 98
issue of Chaos - about how drugs (Class I (Na channel blockers)
and III ( K channel blockers) antiarrhythmic drugs) can increase the
likelihood of Sudden Cardiac Death. The manuscript never made it to
publication, for a variety of reasons.
But, rather than sit of the results,
I have decided to outline the main ideas here - mostly as an experiment
to explore the possibility to makes these results web-accessible.
The primary purpose for this manuscript was to review the basic mechanisms
associated with wave fragment formation - in the setting of supposedly
antiarrhythmic drugs. What we uncovered was that all Class I antiarrhythmic
drugs significantly extend the Vulnerable Period, the interval during which
premature stimulation leads to wave fragmentation and spiral formation.
Moreover, the degree of prolongation is directly proportional to the
unbinding rate constant of the drug. So the guarded receptor model of
drug-channel blockade provides a direct mechanism for assessing the
rates of blocking and unblocking, from which the proarrhythmic potential
can be computed. The main result is that any agent that extends the
refractory period by Na channel blockade will INCREASE the vulnerable period.
Thus the "antiarrhythmic" mechanism for suppressing PVC, in fact is also
a proarrhythmic mechanism for increasing the likelihood that an unsuppressed
VPC will initiate wave fragmentation, spiral formation and progression to
ventricular fibrillation and SUDDEN CARDIAC DEATH.

Sudden Death ?
Recently Valentine Krinsky invited me to revisit this manuscript. Its amazing
what 4 years of fermentation can do to ideas - and I realized that as much
as it pains me, some of the earlier criticism from Art was justified.
So I set about
resolving some areas of ambiguity, and decided the best place for this was
Pushchino. So, the day after Thanksgiving, 2000, I was off to see my
colleagues in Pushchino and to have 2 or 3 weeks of peace and quiet in order
to sort out this manuscript. The first reading (after 4 years) was the
realization that 1 paper = 1 idea , and this paper had too many ideas. So
I extracted everything except the work on the vulnerable period and then
realized that there was a big missing chunck of insight - why was the
use-dependent VP > reduced gNa VP given the same conduction velocity. The
result is was a much better paper and
maybe even Art would agree. For those wishing for a contemporary view of
Pushchino life, visit here
To my knowledge, the basic ideas outlined below are correct (after all
the ideas are motivated by the physics of drug-channel interactions,
and the physics of wave formation and propagation) and
applicable to clinical trials of drugs that block ion channels.
The main idea is that arrhythmias start by either a group of cells
that decide to spontaneously oscillate - or by creating wave
fragments. Wave fragmentation can occur spontaneously (at least in models -
see Alain Karma's work: Phys Rev Lett 71:1103-1106, 1993 Spiral
Breakup in Model Equations of Action Potential Propagation in Cardia
Tissue), by wave-obstacle collisions (see Kostya Agladze's paper in
Science 264:1746-1748, 1994; Rotating spiral waves created by geometry;
or
Starobin and Starmer,
Phys Rev E 54:430-437, 1996; Boundary-layer
analysis of waves propagating in an excitable medium: medium conditions for
wave-front-obstacle separation ) or by stimulation
within the vulnerable period (Starobin, Zilberter and Starmer, Physica D
70:321-341, 1994 - Vulnerability in one-dimensional excitable media).
Here we focus on the VP - and its extension by "anti-arrhythmic" drugs. The
drug model was proposed by our group in 1983
( Starmer, C.F. and Grant, A.O. Phasic ion channel blockade:
A kinetic model and method for parameter estimation. Molecular
Pharmacology 28:348-356, 1985) and has since been validated
by a large number of groups
( see for instance -
Starmer, C.F., Yeh, J.Z. and Tanguy, J. A quantitative description of
QX222 blockade of sodium channels in squid giant axon. Biophysical J.
49:913-920, 1986;
Gilliam, F.R., Starmer, C.F. and Grant, A.O.
Blockade of rabbit atrial
sodium channels by lidocaine: characterization of continuous and
frequency-dependent blockade. Circulation Research 65:723-739, 1989;
Whitcomb, D.C., Gilliam, F.R., Starmer, C.F. and Grant, A.O. Marked QRS
complex abnormalities and sodium channel blockade by propoxyphene
reversed with lidocaine. Journal of Clinical Investigation 84:1629-1636,
1989).
The vulnerable period was described by Art Winfree in
"When Time Breaks Down" and studied numerically by us in the setting of
use-dependent drugs
(Starmer, C.F., Lastra, A.A., Nesterenko, V.V. and Grant, A.O.
A proarrhythmic response to sodium channel blockade: Theoretical
model and numerical experiments. Circulation 84:1364-1377, 1991.
Starmer, C.F., Biktashev, V.N., Romashko, D.N., Stepanov, M.R.,
Makarova, O.N. and Krinsky, V.I. Vulnerability in homogeneous
excitable media: Analytical and numerical studies of unidirectional
propagation, Biophysical Journal, 65:1775-1787, 1993). As a result
of conversations between me and Vicente Perez-Munuzuri, Vicente's
group explored vulnerability experimentally in the BZ medium
( Gomez-Gesteira, M., Fernandex-Garcia, G., Munuzuri, A.P.,
Perez-Munuzuri, V, Krinsky, V.I., Starmer, C.F. and Perez-Villar, V.
Vulnerability in excitable Belousov-Zhabotinaky medium: From 1D to 2D.
Physica D 76:359-368, 1994) and more recently we propsed
theoretical framework:
(Starobin, J., Zilberter, Y.I. and Starmer, C.F. Vulnerability in
one-diensional excitable media, Physica D 70:321-341, 1994. )
In addition, we experimentally verified
the modulation of the vulnerable period by Na channel blockers in 1992
(Starmer, C.F., Lancaster, A.R., Lastra, A.A. and Grant. A.O. Cardiac instability amplified by use-dependent Na channel blockade. American Journal of
Physiology 262:H1305-H1310, 1992;
Nesterenko, V.V., Lastra, A.A., Rosenshtraukh, L.V. and Starmer, C.F.
A proarrhythmic response to sodium channel blockade: The influence of
antiarrhythmic drugs on the window of vulnerability in guinea-pig myocardium.
Journal of Cardiovascular Pharmacology 19:810-820, 1992).
One reviewer found our hypothesis overly simplistic, an interesting
observation in light of experimental verification of all the ideas discussed
below.
Cellular Responses to Na Channel Blockade
As shown below, normally a cardiac cell responds to stimulation
by switching its membrane potential (Vm), generating anaction potential.
Because the time constant of recovery from
Na channel inactivation (h and j) is much longer than the time constant of
recovery of activaiton (m), there is a refractory period - as illustrated.
The cell is unexcitable until the membrane potential has returned to
the rest potnetial as shown below.
Refractor Period Without Drug
When one blocks Na channels, particularly with use-dependent drugs, the
refractory period is prolonged, a reflection of the slow unbinding
rate of dissociation of drug from the channel receptor.
Most Class I antiarrhythmics are use-dependent - and selectively bind
to either open or inactivated channels - and when the channel is not
in a bindable conformation - the drug unbinding time constant is prolonged -
thus prolonging the refractory period as shown here.
Prolonged Refractory Period With Class I Drugs
Because of the use-dependent nature of channel blockade, membrane responses
are sensitive to stimulation rate as shown here - where the stimulation
rate is is sufficiently rapid that the refractory period is extended into
the time of the next stimulus - thus producing an alternating pattern of
cellular responses as shown here.
Alternans
A Model of the Cardiac Vulnerable Period
The cardiac vulnerable period has long been a difficult concept to
visualize. If you assume a uniform medium then the
critical question is how to start a reentrant
wave of activation. In mathematical terms, how to create a phase
singularity. In many textbooks, one finds a triangle of conducting tissue -
where one leg of the triangle is transiently refractory - due to prior
stimulation. This model requires inhomogeneities in refractory properties
which certainly exist in cardiac tissue, but
such inhomogeneities are unnecessary as shown below. Specifically
Wiener showed that in any system with a traveling refractory tail,
it is possible (in 2 dimensional medium) to create a phase singularity
by stimulating in the region where the media excitabilty changes from
non-excitable (due to the refractory state) and excitable (caused by
slightly longer time for the refractory state to switch to a rest state).
Because there is a critical liminal region that must be excited in order
for any wave to successly propagate, there is a time, when the
stimulus field spans the transition from non-excitable to excitable - thus
resulting in a wave the cannot propagate in some directions and can
propagate in other directions as shown below. Art Winfree drew a picture
of this process in "When Time Breaks Down" and gave meat to the
Weiner skeleton. Because a finite interval
of time is required for the critical point to traverse the suprathreshold
region of the stimulus field, there is a finite period of vulnerability
which can be approximated by VP = (L - Lliminal)/v.
Vulnerable Period Model
Shown here is an action potential propagating along a cable, from left
to right (top). Also shown is the front of inactivation (top). At rest,
the tissue is fully excitable, and virtually all cells are available for
conduction (not inactivated). Upon excitation, channels become inactivated
and the cells are transiently unexcitable. At the bottom of the figure
is the electric field generated by a stimulating electrode. Note
that the field decays exponentially on either side of the site. The
middle region of the field is above the stimulation threshold while
the region more perpherial is sub-threshold. Now, the critical point is
to understand that as the cell recovers from channel inactivation, there
is a critical point where medium to the left if excitable and medium to
the right is not excitable. When this point falls within the
suprathreshold region of the stimulation field, a wave will propagate
retrograde (away from the initial wave) and fail to propagate toward
the initial wave (antegrade). Clearly, if the cable ends were joined, then
this wave would circulate. In fact, in 2D and 3D, such partially
propagating waves evolve into spiral waves that reflect the main
features of a reentrant cardiac arrhythmia.
The duration of the vulnerable period is determined by the time the
critical point, P, to pass through the suprathreshold stimulus region.
The vp can be approximated by VP = (L - Lliminal)/v where L is the
length of the
suprathreshold region and v is the velocity of the conditioning wave.
Thus anything that slows propagation is proarrhythmic and increases
the period of vulnerability.
However, the use-dependent properties of Class I drugs further amplify the
vp because of drug-uptake during the time of front formation following
premature stimulation. We indicate above, the virtual electrode
extension, required to increase the excitability sufficient to
support establishing stable wave motion. The boundaries of the
vulnerable period can be readily demonstrated with numerical
experiments. Here are 5 ms snapshots of the spatial distritution of
the membrane potential, showing the tail of the conditioning wave (traveling
from left to right) and the responses to test stimuli.
Demonstration of the Cardiac Vulnerable Period
Vulnerable Period without Drug
Here,note that reducing gNa slows propagation and thus slows the time
required for the critical point, P, to pass through the suprathreshold
region - in concert with VP = L/v. However there
is something quite interesting happening. Note the time required to
establish stable propagation at the uni-bi directional conduction boundary.
For gNa = 4.0, only 10 - 15 ms are required - whereas for gNa = 2.0, near
the threshold of propagation, more than 50 ms are required. This suggests
that the VP is not only dependent on the velocity of the conditioning
wave, but also on the gradient of excitability at the s2 stimulation
site.
Vulnerable Period Boundaries with Drug
Here, the effect of conduction velocity is factored out of the experiment - by
introducing a test stimulus immediately after the passage of the first
conditioning wave. Because the initial conditions were set at zero blockade,
the conduction velocity of the conditioning wave was essentially that of
the drug-free experiment. Shown above is an increase in the VP from 5 ms
to 15 ms - with the same conduction velocity. Where did the additional
VP extension come from? My current hypothesis is that this is
the result of the small gNa gradient at the s2 test site - and thus, the
time required to establish stable propagation is much longer than in
the drug-free situation. Thus, antiarrhytymic drugs are double-edged
agents - they are supposedly antiarrhythmic by suppressing excitability,
but are proarrhythmic by slowing conduction AND extending the time
required for stable propagation to develop. Not a good situation.
This effect can be readily appreciated below. Note that the VP vs 1/v
relationship is linear for both gNa changes and for use-dependent
drug. The drug line, though, is offset by approximatly 15 ms - the
time required (for this drug) to develop stable propagation. I've been
puzzled by this graph ever sense I made it 12 years ago - and finally
noticed the effect on the left side of the time plots of front develoopment
(above). I'm a slow learner!
So - is this model of vulnerability real? How to test the idea. IF its
correct, then it should be possible to identify the critical point, P,
as the common intersection of Na channel availability, for different
availability conditions - and the simplest is to change GNa - the maximum
sodium channel conductance. Below is a trace of the availability (top)
and the action potential, at the bottom - demonstrating a common intersection
of availability - associated with the transition from block to uni-directional
conduction. (The scale for channel availability is 15x, and the membrane
potential traces are at 5 ms intervals (at the s2 site) - the tails are
from individual action potentials and I apologize for the complexity).
Identifying the
critical Na channel availability
Role of availability gradient in front formation
Here we show the role of the availability gradient on the formation time
of the antegrade wave. Shown are 2 conductances: 5 (control) and 2
(marginally excitable). Each trace of the propagating action potential
is a snapshot of the spatial membrane potential distribution, taken every
5 ms. Note the slow process of stable propagation for the marginally
excitable medium, coupled with slow propagation - while for the normal
Na channel availability, s2 antegrade front formation is rapid and propagation
is fast.
Comparing steep and shallow gradient effects on front formation
The distance that the critical point, P, must travel in order to produce
a stable antegrade wave, extends the vulnerable region, and is the major
determinant of the danger in slowly unbinding Class 1 antiarrhythmics. From
a mechanistic point of view, the class 1 antiarrhythmics with the slowest
unbinding process appears to be the open channel blockers, where the drug
is trapped within the channel during the diastolic interval. This
extension of the vulnerable region accounts for the upward shift in the
VP - 1/velocity relationship displayed below
Summary of Use-Dependent Drug Extension of the Cardiac VP
Summary Results
Here I plot the vulnerable period for for different values of gNa (continuous
blockade) and for different stimulus intervals of a use-dependent drug - as a
function of the reciprocal conduction velocity. Our theory predits a linear relationship
between vp and 1/velocity - and this was observed in our numerical experiments
with use-dependent blockade, but not for continuous blockade.
What is very interesting is that for the same conduction velocity, we
observed a dramatic increase in the vp for
use-dependent drugs over that associated with a simple reduction
in gNa (secondary to depolarizing the rest potential or a reduced expression
of Na channels). Why? - it seems that
there is a very interesting interaction between drug uptake during
formation of the front initiated by premature stimulation - that results
in additional prolongation of the vp.
Perhaps this is significant with respect to
the CAST study? - I am working on this problem (as we speak) and the work
above, demonstrating the variation in front formation time, as a function
of channel availability (and its gradient) seems relevant.
Here, we confirm the gradient effect on the VP extension by exploring
the VP following the first conditioning pulse, and varying the unbinding
rate constant for a use-dependent channel blocking agent. Note the linear
extension with the unbinding rate. This is easy to see with a little algebra.
The gradient of availability, after inactivation recovery is d gNa*(1-b)/dx
and, from the model of ion channel blockade: db/dt = kD(1-h)(1-b) - lb.
Because the channel binding sites are inaccessible at the rest potential,
the association term drops out and so db/dt = -lb an unbinding process. Now
gNa*(1-b) must cross the critical value - so its possible to compare the
gradients simply by realizing the the unbinding rate constant is proportional
to the derivative (db/dt) - since b is determined by the critical point P - and
is independent of the maximum conductance. Thus
the gradient is -db/dt / dx/dt or -1/v db/dt = - "el"/v. The inverse gradient,
thus is proportional to 1 / db/dt is the reciprocal
rate constant, l. The time constant of unbinding, t is 1/l. Here we plot
the unbinding time constant against the VP and see a reasonably nice linear
fit. This linear relationship is quite reassuring, given all the assumptions
required to extimate the gradient.
Now, if you fully understand drug effects and the vulnerable period,
its time to see what
happens when you stimulate within the vulnerable region following a
conditioning wave. Here is an aged link to some notes where I explored
initiating spiral waves within the VP in FHN medium and then in the Beeler
Reuter cardiac medium. The BR clips include the computed ECG which
shows the transition from monomorphic to polymorphic configurations, following
the transition from a stable circular core to an unstable, meandering of
the spiral tip. The physics of this was discovered by Josef Starobin and
described in our papers in Phys Rev E.
Try your hand at viewing vulnerability in a 2D
medium and the evolution of a spiral with FitzHugh Nagumo medium
Copyright 1997-2003 C. Frank Starmer